Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine

Part of paid clinical trials in Greenville, South Carolina.

Sponsor
Prisma Health-Upstate
Study ID
NCT07202039
Status
Recruiting

Conditions

  • Sweet Non-cooling EC
  • Sweet-Cooling EC
  • Tobacco-flavored EC

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Brief individual counseling sessions — BEHAVIORAL
    Five brief, individual counseling sessions will provide education, behavioral support, and motivational strategies to facilitate switching from combustible cigarette use to EC

Study Details

This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine

Key Dates

Start date
Apr 29, 2026
Status verified
May 2026
Primary completion
Mar 30, 2029
Completion
Jun 29, 2029

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Sweet-Cooling EC + Counseling
    Those randomized to the intervention group will be provided a free 12-week supply of sweet-cooling electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.
  • Experimental: Sweet non-cooling EC + Counseling
    Those randomized to the intervention group will be provided a free 12-week supply of sweet non-cooling electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.
  • Active Comparator: Tobacco-flavored EC + Counseling
    Those randomized to the intervention group will be provided a free 12-week supply of tobacco-flavored electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.

Primary Outcome Measure

Change in cigarettes smoked per day [ Time Frame: Baseline to week 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Addiction Medicine CenterGreenvilleSouth Carolina29605
Alain Litwin, MD
864-455-5648

Find similar trials in Greenville, SC